Quick Answer
VERTEX PHARMACEUTICALS INC / MA reported Cash And Cash Equivalents At Carrying Value of $5.08 billion for the year ending 2025.
- VERTEX PHARMACEUTICALS INC / MA showed an increase of +11.3% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
- This data is from VERTEX PHARMACEUTICALS INC / MA's annual report (Form 10-K), filed with the SEC on February 13, 2026.
- XBRL data for this metric is available from 2012 to 2025 (14 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 14 years of available data (2012 to 2025), VERTEX PHARMACEUTICALS INC / MA's Cash And Cash Equivalents At Carrying Value has grown by 939.0%.
- Historical annual values: Fiscal year 2025: $5.08 billion | Fiscal year 2024: $4.57 billion | Fiscal year 2023: $10.37 billion | Fiscal year 2022: $10.50 billion | Fiscal year 2021: $6.80 billion | Fiscal year 2020: $5.99 billion | Fiscal year 2019: $3.11 billion | Fiscal year 2018: $2.65 billion | Fiscal year 2017: $1.67 billion | Fiscal year 2016: $1.18 billion | Fiscal year 2015: $714.77 million | Fiscal year 2014: $625.26 million | Fiscal year 2013: $569.30 million | Fiscal year 2012: $489.41 million.
- Data sourced from SEC EDGAR public filings as of June 24, 2026.
Last verified: